[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-514818-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-514818-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","melanoma-institute-australia-and-melanoma-patients-australia-final-report-february-2022","Melanoma Institute Australia and Melanoma Patients Australia - Final Report - February 2022","","Final Report (February 2022) commissioned by Melanoma Institute Australia and Melanoma Patients Australia and prepared independently by Insight Economics. Joint funding is provided by Bristol Myers Squibb, MSD, Novartis and Melanoma Institute Australia. The report presents an analysis of melanoma across Australia, including epidemiology, prevention and awareness, research, early detection, diagnosis and treatment, supportive care and survivorship, and an action plan to reduce melanoma mortality. It also includes scorecard-based assessments and recommended actions, supported by appendices with projections, survey results, consultation input, a glossary, and bibliography.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/melanoma-institute-australia-and-melanoma-patients-australia-final-report-february-2022/514818/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/melanoma-institute-australia-and-melanoma-patients-australia-final-report-february-2022/514818.png","ImageObject",300,407,{"name":42,"@type":43},"\tJames","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-04","2026-10-06",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Who commissioned and prepared the final report, and who provided funding?","Question",{"text":63,"@type":64},"The report was commissioned by Melanoma Institute Australia and Melanoma Patients Australia. It was prepared independently by Insight Economics, with joint funding provided by Bristol Myers Squibb, MSD, Novartis and Melanoma Institute Australia.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which aspects of melanoma care and impact does the report cover?",{"text":68,"@type":64},"It covers Australia’s cancer profile of melanoma, prevention and awareness, melanoma research, early detection, diagnosis and treatment, supportive care and survivorship, and the design of an action plan to end melanoma mortality.",{"name":70,"@type":61,"acceptedAnswer":71},"What does the report’s approach include to guide improvements?",{"text":72,"@type":64},"Each major domain is assessed with performance and areas for improvement and concludes with scorecard assessment and recommended actions. The report also includes an action plan with pathways for implementation, plus appendices such as projections, patient and carer survey results, and stakeholder consultation outputs.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},514818,1791467080,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,109,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":107,"slug":108},40,"healthcare",{"id":110,"doc_module":4,"doc_module_name":25,"category_name":111,"show_sort_weight":112,"slug":113},8,"Research & Report",30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":4},2336474466412,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Final Report  \nFebruary 2022  \nThis report was commissioned by Melanoma Institute Australia and Melanoma Patients Australia.  \nThe report was prepared independently by Insight Economics.  \nFunding for this report was jointly provided by Bristol Myers Squibb, MSD, Novartis and Melanoma Institute Australia.  \nDisclaimer: While Insight Economics endeavours to provide reliable analysis and believes the material it presents is accurate, it will not be liable for any claim by any party acting on such information.  \n© Insight Economics 2022  \nContents  \nAcknowledgements vii  \nThe Sunbaker xi  \nReport on a Page xiii  \nExecutive Summary xiv  \nChapter 1  \nAustralia’s Cancer: Melanoma 1  \n1.1 What is melanoma? 1  \n1.2 Risk factors 2  \n1.3 Signs and symptoms 3  \n1.4 Stages of melanoma 4  \n1.5 Incidence and mortality 6  \n1.6 How is melanoma diagnosed and treated? Australian clinical guideline recommendations 9  \nChapter 2  \nReducing the impact ofmelanoma on Australian patients and communities: a call to action 11  \n2.1 Eliminating deaths from melanoma is within Australia’s reach 11  \n2.2 The case for change: the costs ofthe status quo are high 11  \n2.3 Drastically reducing the impact of melanoma in our lifetimes: evaluating Australia’s performance to date and identifying priorities for Australian communities 14  \nChapter 3  \nPrevention and awareness: performance and areas for improvement 17  \n3.1 Australian successes in melanoma prevention 17  \n3.2 Remaining gaps in prevention and awareness 20  \n3.3 Opportunities to improve prevention and awareness 34  \n3.4 Impact of closing the gaps in prevention 41  \n3.5 Conclusions: Scorecard assessment and recommended actions to improve melanoma prevention and awareness 42  \nChapter 4  \nMelanoma research in Australia: performance and next horizon opportunities 45  \n4.1 Australian successes in melanoma research 45  \n4.2 Major research questions in melanoma and Australia’s role 50  \n4.3 Barriers to realising research impact 65  \n4.4 Return on investment in melanoma 70  \n4.5 Conclusions: Scorecard assessment and recommended actions  \nto accelerate melanoma research 71  \nChapter 5  \nEarly detection of melanoma: performance and areas for improvement 73  \n5.1 Australian successes in early detection of melanoma 73  \n5.2 Areas for improvement in early detection of melanoma 74  \n5.3 Opportunities to improve early detection 83  \n5.4 Impacts from improving early detection 87  \n5.5 Conclusions: Scorecard assessment and recommended actions to improve early detection of melanoma 88  \nChapter 6  \nDiagnosis and treatment: performance and areas for improvement 91  \n6.1 Australian successes in diagnosis and treatment 91  \n6.2 Areas for improvement in diagnosis and treatment 94  \n6.3 Opportunities to improve outcomes in diagnosis and treatment 107  \n6.4 Impacts from improvements in the diagnosis and treatment of melanoma 112  \n6.5 Conclusions: Scorecard assessment and recommended actions to improve treatment of melanoma 113  \nChapter 7  \nSupportive Care and Survivorship: performance and areas for improvement 115  \n7.1 What are supportive care and survivorship, and why are  \nthey so important? 115  \n7.2 Increasing incidence and survival is leading to exponential growth in melanoma patients and survivors needing support 119  \n7.3 Australian progress in supportive care and survivorship 119  \n7.4 Areas for improvement in supportive care and survivorship 120  \n7.5 Opportunities to improve supportive care and survivorship 127  \n7.6 Impacts of improved access to supportive care and survivorship 129  \n7.7 Conclusions: Scorecard assessment and recommended actions to improve early detection of melanoma 130  \nChapter 8  \nA Plan ofAction to end mortality from melanoma: performance, priorities, payoffs and pathways 131  \n8.1 Summary of Australia’s performance and opportunities for improvement 131  \n8.2 Action plan to eliminate melanoma as we know it 134  \n8.3 Impacts of action 143  \n8.4 Pathways for implementation 145  \n8.5 Prioritie","cbCaiqK1uH7Dlv0F","https://ap.wps.com/l/cbCaiqK1uH7Dlv0F","pdf",7792723,223,"English","# Executive Summary\n# Chapter 1 Australia’s Cancer: Melanoma\n## 1.1 What is melanoma?\n## 1.6 How is melanoma diagnosed and treated? Australian clinical guideline recommendations\n# Chapter 2 Reducing the impact of melanoma on Australian patients and communities: a call to action\n## 2.1 Eliminating deaths from melanoma is within Australia’s reach\n# Chapter 3 Prevention and awareness: performance and areas for improvement\n## 3.5 Conclusions: Scorecard assessment and recommended actions to improve melanoma prevention and awareness\n# Chapter 4 Melanoma research in Australia: performance and next horizon opportunities\n## 4.5 Conclusions: Scorecard assessment and recommended actions to accelerate melanoma research\n# Chapter 5 Early detection of melanoma: performance and areas for improvement\n## 5.5 Conclusions: Scorecard assessment and recommended actions to improve early detection of melanoma\n# Chapter 6 Diagnosis and treatment: performance and areas for improvement\n## 6.5 Conclusions: Scorecard assessment and recommended actions to improve treatment of melanoma\n# Chapter 7 Supportive Care and Survivorship: performance and areas for improvement\n## 7.7 Conclusions: Scorecard assessment and recommended actions to improve early detection of melanoma\n# Chapter 8 A Plan of Action to end mortality from melanoma: performance, priorities, payoffs and pathways\n## 8.5 Priorities for action\n# Appendices\n## Appendix A Incidence, mortality, survivorship and cost projections\n## Appendix B Survey of Melanoma Patients and Carers\n## Appendix C Stakeholder Consultation and Consumer Forums\n## Appendix D Glossary\n## Appendix E Bibliography","[{\"question\":\"Who commissioned and prepared the final report, and who provided funding?\",\"answer\":\"The report was commissioned by Melanoma Institute Australia and Melanoma Patients Australia. It was prepared independently by Insight Economics, with joint funding provided by Bristol Myers Squibb, MSD, Novartis and Melanoma Institute Australia.\"},{\"question\":\"Which aspects of melanoma care and impact does the report cover?\",\"answer\":\"It covers Australia’s cancer profile of melanoma, prevention and awareness, melanoma research, early detection, diagnosis and treatment, supportive care and survivorship, and the design of an action plan to end melanoma mortality.\"},{\"question\":\"What does the report’s approach include to guide improvements?\",\"answer\":\"Each major domain is assessed with performance and areas for improvement and concludes with scorecard assessment and recommended actions. The report also includes an action plan with pathways for implementation, plus appendices such as projections, patient and carer survey results, and stakeholder consultation outputs.\"}]","Melanoma Institute Australia and Melanoma Patients Australia - Final Report - February 2022 | PDF",1791302294,562]